CTXR Citius Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CTXR

Price (delayed)

$0.5686

Market cap

$15.61M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.78

Enterprise value

$5.74M

?
Relative Growth: Rel. Growth: 20
Relative Strength: Rel. Strength: 16
Relative Valuation: Rel. Valuation: 19
Relative Profitability: Rel. Profitability: 22

Citius Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. Citius Pharma owns approximately 71% of Citius Oncology. In December 2025, Citius ...

Highlights
Citius Pharmaceuticals's quick ratio has surged by 183% YoY
The EPS has surged by 64% year-on-year and by 21% since the previous quarter
The net income is down by 15% year-on-year
Citius Pharmaceuticals's gross margin has decreased by 3.5% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.citiuspharma.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of CTXR

CTXR stock price

How has the Citius Pharmaceuticals stock price performed over time
Intraday
-4.95%
1 week
1.54%
1 month
-5.26%
1 year
-50.56%
YTD
-26.82%
QTD
-5.94%

Financial performance

How have Citius Pharmaceuticals's revenue and profit performed over time
Revenue
$7.11M
Gross profit
$5.5M
Operating income
-$61.38M
Net income
-$46.27M
Gross margin
77.3%
Net margin
-651.3%
The operating income fell by 49% YoY and by 5% QoQ
The revenue has grown by 27% from the previous quarter
The gross profit rose by 22% since the previous quarter
CTXR's net margin is up by 21% QoQ

Price vs fundamentals

How does CTXR's price correlate with its fundamentals

Growth

What is Citius Pharmaceuticals's growth rate over time

Valuation

What is Citius Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.23
P/S
2.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.81
The EPS has surged by 64% year-on-year and by 21% since the previous quarter
The price to book (P/B) is 79% lower than the 5-year quarterly average of 1.2 and 17% lower than the last 4 quarters average of 0.3
Citius Pharmaceuticals's equity has increased by 8% QoQ and by 2.4% YoY
The revenue has grown by 27% from the previous quarter

Efficiency

How efficient is Citius Pharmaceuticals business performance
The return on sales is up by 20% since the previous quarter
CTXR's ROE is down by 7% YoY
The company's return on assets rose by 2.6% QoQ
The ROIC has grown by 2.2% from the previous quarter

Dividends

What is CTXR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CTXR.

Financial health

How did Citius Pharmaceuticals financials performed over time
Citius Pharmaceuticals's total assets is 114% higher than its total liabilities
Citius Pharmaceuticals's quick ratio has surged by 183% YoY
Citius Pharmaceuticals's current ratio has surged by 79% YoY and by 45% QoQ
CTXR's debt is 89% lower than its equity
Citius Pharmaceuticals's equity has increased by 8% QoQ and by 2.4% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.